B. Riley raised the firm’s price target on Eton Pharmaceuticals (ETON) to $26 from $24 and keeps a Buy rating on the shares. The company reported strong Q1 results across its portfolio, the analyst tells investors in a research note. The firm continues to view the reaffirmed $80M year-end run-rate guidance as conservative, and sees “two high-conviction opportunities to drive upward revisions” closer to $100M.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON:
- Eton Pharmaceuticals’ Earnings Call: Growth and Prospects
- Eton Pharmaceuticals price target raised to $28 from $26 at Craig-Hallum
- Eton Pharmaceuticals: Buy Rating Backed by Successful Relaunches and Promising Growth Prospects
- Eton Pharmaceuticals Reports Strong Q1 2025 Growth
- Eton Pharmaceuticals reports Q1 EPS 7c, consensus 5c